Compare PRI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PRI | ABVX |
|---|---|---|
| Founded | 1927 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Life Insurance | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.6B |
| IPO Year | N/A | N/A |
| Metric | PRI | ABVX |
|---|---|---|
| Price | $257.66 | $117.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $304.25 | $115.83 |
| AVG Volume (30 Days) | 233.4K | ★ 1.7M |
| Earning Date | 11-05-2025 | 08-11-2025 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | ★ 65.97 | N/A |
| EPS | ★ 21.75 | N/A |
| Revenue | ★ $3,335,204,000.00 | $6,231,374.00 |
| Revenue This Year | $4.64 | $6.80 |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $11.89 | ★ N/A |
| Revenue Growth | ★ 10.41 | N/A |
| 52 Week Low | $230.98 | $4.77 |
| 52 Week High | $298.75 | $138.49 |
| Indicator | PRI | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 51.08 |
| Support Level | $256.40 | $108.53 |
| Resistance Level | $263.12 | $138.49 |
| Average True Range (ATR) | 4.66 | 7.25 |
| MACD | 0.72 | -1.73 |
| Stochastic Oscillator | 62.59 | 28.51 |
Primerica Inc is a provider of financial services to middle-income households in the United States and Canada. The company offers life insurance, mutual funds, annuities, and other financial products, distributed on behalf of third parties. Primerica has three main subsidiaries: Primerica Financial Services, a marketing company; Primerica Life Insurance Company, a principal life insurance underwriting entity; and PFS Investments, which offers investment and savings products, brokerage services, and registered investment advisory. It has three segments Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. Geogriphically, it derives a majority of its revenue from the United States.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.